Clinical trial · Observational
Retrospective Study in a NSCLC M+ p
Observational Retrospective Study to Describe the Management of Advanced or Metastatic EGFR (Epidermal Growth Factor Receptor) Mutated Non-small Cell Lung Cancer Patients in Spain
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a national, multicentre, non-interventional, retrospective study to be carried out in the oncology settings of approximately 15-20 Spanish hospitals. At each participant hospital, all patients recently diagnosed with advanced EGFR mutated NSCLC (both newly or with recurrent disease , without previous treatment for metastatic disease) from April 2010 to December 2011 will be included as study population. Information about the follow-up of the patients during a minimum of 12 months after diagnosis will be collected.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| EGFR Mutated Non-small Cell Lung Cancer Patients | Lung Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Description of management patterns (clinical and diagnostic) of advanced/metastatic EGFR M+ NSCLC patients in Spain.
- timeFrame
- 32 months
Secondary outcomes (6)
- measure
- Description of use of resources related with the management of advanced/metastatic EGFR M+ NSCLC patients in Spain.
- timeFrame
- 32 months
- measure
- Evaluation of overall response rate (ORR).
- timeFrame
- 32 months
- measure
- Evaluation of disease control rate (DCR).
- timeFrame
- 32 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed newly locally advanced or metastatic NSCLC (stage IIIB/IV) * Confirmed EGFR mutation by a validated test * Availability of medical record Exclusion Criteria: * Participating on a blinded randomized clinical trial at any time during the study period * Pregnant women (due to they do not reflect daily clinical practice)
References
Publications (0)
Data not yet available